S&CO Inc. lessened its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 0.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 401,209 shares of the biopharmaceutical company’s stock after selling 1,980 shares during the period. Bristol-Myers Squibb comprises approximately 2.8% of S&CO Inc.’s portfolio, making the stock its 8th biggest position. S&CO Inc.’s holdings in Bristol-Myers Squibb were worth $24,907,000 at the end of the most recent quarter.
Several other institutional investors have also modified their holdings of the company. Raymond James Financial Services Advisors Inc. boosted its position in Bristol-Myers Squibb by 2.6% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 412,476 shares of the biopharmaceutical company’s stock valued at $22,827,000 after purchasing an additional 10,456 shares during the last quarter. Toronto Dominion Bank boosted its position in Bristol-Myers Squibb by 19.1% during the second quarter. Toronto Dominion Bank now owns 1,062,979 shares of the biopharmaceutical company’s stock valued at $58,813,000 after purchasing an additional 170,360 shares during the last quarter. SFE Investment Counsel boosted its position in Bristol-Myers Squibb by 8.6% during the third quarter. SFE Investment Counsel now owns 16,375 shares of the biopharmaceutical company’s stock valued at $1,017,000 after purchasing an additional 1,290 shares during the last quarter. Aperio Group LLC boosted its position in Bristol-Myers Squibb by 9.9% during the third quarter. Aperio Group LLC now owns 928,404 shares of the biopharmaceutical company’s stock valued at $57,635,000 after purchasing an additional 83,708 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in Bristol-Myers Squibb by 1.9% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 123,418 shares of the biopharmaceutical company’s stock valued at $6,830,000 after purchasing an additional 2,323 shares during the last quarter. 72.54% of the stock is owned by institutional investors and hedge funds.
NYSE BMY opened at $53.39 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.40 and a current ratio of 1.53. The stock has a market cap of $86.49 billion, a price-to-earnings ratio of 17.74, a P/E/G ratio of 1.48 and a beta of 1.08. Bristol-Myers Squibb Co has a fifty-two week low of $46.94 and a fifty-two week high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.18. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. Bristol-Myers Squibb had a return on equity of 47.89% and a net margin of 6.50%. Analysts anticipate that Bristol-Myers Squibb Co will post 3.88 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, November 1st. Stockholders of record on Friday, October 5th were paid a $0.40 dividend. The ex-dividend date of this dividend was Thursday, October 4th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 3.00%. Bristol-Myers Squibb’s payout ratio is presently 53.16%.
Several equities analysts have weighed in on the company. Morgan Stanley cut their target price on Bristol-Myers Squibb from $63.00 to $59.00 and set a “hold” rating on the stock in a report on Tuesday. BMO Capital Markets cut their target price on Bristol-Myers Squibb from $57.00 to $54.00 and set a “market perform” rating on the stock in a report on Tuesday, October 23rd. Wolfe Research assumed coverage on Bristol-Myers Squibb in a report on Tuesday, October 23rd. They set an “outperform” rating and a $66.00 target price on the stock. William Blair restated an “outperform” rating on shares of Bristol-Myers Squibb in a report on Monday, October 22nd. Finally, Citigroup lowered Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their target price for the company from $62.00 to $57.00 in a report on Monday, October 22nd. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the company. Bristol-Myers Squibb currently has a consensus rating of “Hold” and an average price target of $62.48.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/11/10/bristol-myers-squibb-co-bmy-shares-sold-by-sco-inc.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Featured Article: How to Invest in the Dividend Aristocrat Index
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.